Panmure Liberum raises Hikma target price to 1,900p

What Brokers Say Health Written by: Ian Lyall 15:30 Fri 04 Sep 2026 --> Edited by: Jamie Ashcroft Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business output at the Daily... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Hikma Pharmaceuticals PLC ( LSE:HIK OTC:HKMPF ) View Price & Profile Panmure Liberum raises Hikma target price to 1,900p Published: 15:30 04 Sep 2026 BST Panmure Liberum has raised its target price for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) from 1,600p to 1,900p, saying the drugmaker’s strong first-half results support further upside in its shares. The broker said Hikma’s recent interim results were reassuring, with the only surprises coming on the upside and beats reported across the business. Panmure Liberum said the next stage of a rerating would depend on Hikma delivering against its financial year 2026 forecasts. It slightly raised its earnings before interest and tax forecasts to reflect the strong first-half performance, while making no material changes to its broader forecasts. Panmure Liberum said its forecasts remained broadly in line with market consensus and also adjusted the timing of its modelling for Hikma’s share buyback. The broker also changed its treatment of capital contributions to Hikma’s prescription medicines contract manufacturing operations, which are recorded as deferred income and released over several years. Hikma shares have risen from their February lows, but Panmure Liberum said it still saw plenty of upside. It identified a second step for the rerating: convincing investors that higher research and development investment can deliver a more predictable earnings trajectory. Panmure Liberum said it believed Hikma could achieve this, but the company still needed to demonstrate that its increased investment would translate into more consistent earnings. Continue reading